

Cancer Council Australia

ABN 91 130 793 725

Full Financial Report
for the year ended 30 June 2020

About Cancer Council Australia

The Cancer Council Federation is Australia's leading non-government cancer control* organisation. The national office, Cancer Council Australia, advises the Australian Government and other bodies on practices and policies to help prevent, detect and treat cancer. Cancer Council Australia also supports its members, the state and territory Cancer Councils, to achieve our shared purpose. Collectively we advocate for the rights of people affected by cancer and in particular for best treatment and supportive care in order to reduce the burden of cancer in the Australian community.

Our vision

A cancer free future.

Our purpose

We are Australia's leading cancer charity, uniting the community, providing support, investing in research and saving lives.

Our activities

Reflecting our stated strategic plan Cancer Council Australia works to:

1. Shape and influence policy and practice across the cancer control continuum
2. Develop and disseminate evidence-based cancer information
3. Convene and collaborate with cross sectorial stakeholders and consumers to set priorities and mobilise action
4. Be a trusted voice for cancer control in Australia.

Our history

Cancer Council Australia commenced in 1961 as the *Australian Cancer Society*, an incorporated association, when the six state Cancer Councils – which then varied in name and brand – agreed to establish a federal body to promote cancer control at the national level. Cancer organisations in the ACT and the Northern Territory were subsequently formed and signed on as members of the Society.

While state and territory Cancer Councils continued to play the predominant role in research, public health, patient support and education programs, the federal body's primary role was to develop independent national cancer control policy – albeit on a comparatively modest scale, in collaboration with our members.

In 1997, the eight jurisdictional members agreed to expand the Society, adopting the trading name of *The Cancer Council Australia* and appointing an expert Chief Executive Officer, Professor Alan Coates, to lead the push for improved national cancer control policy and build the Cancer Council brand and profile. Specialist staff in communications, advocacy, business management, marketing and other professional roles were recruited to promote the organisation's mission.

Over the ensuing decade, state and territory members uniformly adopted the name Cancer Council and together took on the image of the daffodil, a global symbol of hope, as our common logo.

In 2008, the organisation migrated from being registered as an Incorporated Association to a Company Limited by Guarantee, and formalised its registered name as *Cancer Council Australia*.

Cancer Council Australia is also allied with the *Clinical Oncology Society of Australia*, which provides advice on medical and scientific issues, and is a member of the *Australian Chronic Disease Prevention Alliance*, as well as global collaborations such as the *Union for International Cancer Control*.

Over its 59-year history, Cancer Council Australia has transformed from a small secretariat to a strong federal body that has become Australia's leading independent authority on cancer control.

Cancer Council Australia seeks to engage all Australians in our work to reduce the impact of cancer in Australia through advocacy, research, education and support.

*Cancer control refers to actions to reduce the impact of cancer on people including: reducing cancer risk and incidence; improving early detection and treatment; and improving care and support for people affected by cancer.

Cancer Council Australia

(A Company limited by guarantee)

Corporate Information

ABN 91 130 793 725

Patron

Sir Gustav Nossal AC CBE

Directors as at 30 June 2020

Professor Hugh Harley
Mr David Bowker
Mr Roger Buckley
Professor Fran Boyle AM
Ms Annette Burke
Ms Trisha Cashmere
Dr John Laker AO
Professor Jeremy Millar
Ms Jenny Parker
Mr Mark Phillips
Ms Jennifer Richter AM
Associate Professor Marion Saville AM
Ms Patricia Schmidt
Dr Ruth Shean

Company Secretary

Ms Lisa Miskell

Chief Executive Officer

Professor Sanchia Aranda AM

**Registered office and
principal place of business**

Level 14
477 Pitt Street
Sydney NSW 2000

Company contact details

GPO Box 4708
Sydney NSW 2001

P: +61 (0)2 8063 4100
F: +61 (0)2 8063 4101
E: info@cancer.org.au
W: www.cancer.org.au

Auditors

BDO East Coast Partnership
Level 11
1 Margaret Street
Sydney NSW 2000

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report

30 June 2020

The Directors present their report on Cancer Council Australia ("the Company") for the year ended 30 June 2020.

Reflecting the Company's vision and purpose, our object is to advance and achieve the following goals as a charitable institution operating in Australia to:

- i. Promote the prevention and control of cancer;
- ii. Reduce the incidence of preventable cancers;
- iii. Reduce deaths from cancer;
- iv. Foster and support high quality cancer research in Australia; and
- v. Improve survival from cancer.

Consistent with this, Cancer Council Australia is committed to:

- i. Working in partnership with its members;
- ii. Collaborating with people affected by cancer, cancer charities, health care providers, and Government and non-Government agencies to improve cancer control;
- iii. Providing strategic leadership in cancer control;
- iv. Supporting and enabling the charitable work of members, who are themselves charitable entities that have a similar charitable purpose to Cancer Council Australia;
- v. Driving national collaboration and harmonisation in cancer control;
- vi. Being a trusted source of cancer information and evidence in cancer control;
- vii. Being a leader in national and international policy and advocacy in cancer control;
- viii. Fostering partnerships that reduce the impact of cancer on our communities;
- ix. Promoting best practice in all aspects of cancer control; and
- x. Enhancing quality of life for people affected by cancer.

In pursuing these objectives the Company's primary short-term objectives over the reporting period were:

- **Providing leadership, information, and support through COVID-19** – Collaborating within the federation and with external organisations to ensure the needs of people affected by cancer were met during this challenging time
- **Increasing awareness of inequalities and financial toxicity** – Calling for action, driving research and developing cancer control expertise and policy to improve cancer outcomes for all Australians
- **Public health advocacy** – Educating Australians to reduce their cancer risk, with focus on the National Bowel Cancer Screening Program, National Tobacco Strategy, strengthened obesity control policies, skin cancer prevention, and advancing the agenda for occupational cancers
- **Supporting healthcare professionals to deliver optimal care** - Developing and promoting clinical practice guidelines on our wiki platform, and online educational resources for health professionals and supporting the implementation of optimal care pathways
- **Improving public awareness and understanding about the breadth of Cancer Council's services and national impact**

The Year In Review

Given the downturn in fundraising across the Cancer Council Federation as a result of both COVID-19 and the ongoing impact of the bushfires, and the unprecedented impact of COVID-19 on the Australian health and social service systems, Cancer Council Australia adapted its strategic plan to deliver against a plan that meets the objectives of our core mission and is viable given the significant decrease in staff and financial resources. Despite these significant challenges, Cancer Council Australia has continued to deliver against its objectives and meet the needs of people affected by cancer. Key highlights during the year include:

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report (cont'd)

30 June 2020

- Supported by the Australian Government and the federation, our 2019 National Bowel Cancer Screening campaign will prevent up to 1,100 bowel cancers and save up to 600 lives over the next 30 years
- Convening and leading a collaboration of 14 cancer charities across Australia to form a common voice for cancer support during the COVID-19 pandemic
- Developing and translating a 'Cancer and COVID-19' factsheet into 12 different languages to ensure all Australians, including culturally and linguistically diverse communities, had access to credible, expert information during the pandemic
- Developing and launching a new content management system, migrating cancer.org.au, the number one cancer information website in Australia, as well as three additional microsites and consolidating over 1600 pages of content, into a new, user-friendly platform accessible to all Australians

Other achievements during the year include:

- Increasing awareness of our Informed Financial Consent Standard created with our partners the Breast Cancer Network Australia, Prostate Cancer Foundation of Australia, and CanTeen.
- Continuation of the Optimising the Early Detection of Breast Cancer project in collaboration with Breast Screen Australia and the Commonwealth Department of Health.
- Developing a proactive approach to highlighting inequalities in cancer outcomes in the Australian media through commentary on new reports and research.
- Progressing work on our first Reconciliation Action Plan.

We also continued our ongoing priority programs to educate and inform Australians about cancer prevention and support individuals affected by cancer, including:

- Joining with the Australasian College of Dermatologists to remind Australians to protect their skin from UV, during National Skin Cancer Action Week.
- Using World Cancer Day as a platform to promote cancer prevention – joining the Australian Protection Principal Committee in encouraging Australians to quit smoking to reduce their risk of COVID-19 complications.
- Improving supportive care collaboration and data across the federation to better understand opportunities for service improvement.
- Using media channels and digital platforms to encourage Australians to prevent cancer by quitting smoking, using sun protection, maintaining a healthy diet and lifestyle and participating in screening programs.

Principal activities

The principal activities of Cancer Council Australia during the year were focused on furthering our objectives, referenced above. More detail on the achievements against these objectives is provided in the 2019-2020 Annual Report. This financial report pertains only to Cancer Council Australia and does not aggregate income or expenditure across State and Territory members.

Review of financial operations and results of Cancer Council Australia

The total income for the financial year ended 30 June 2020 was \$21,653,653. In the same period, expenditure was \$21,521,851 leaving a surplus of \$131,802. The level of spending for the Company varies from year to year as the range of activities to support our members, and the costs associated with them, also vary. This expenditure includes our investment in health strategies and activities to reduce the impact of cancer, as well as distributions to our members to deliver local programs. Further details are outlined in the Research, Prevention & Support sections of Cancer Council Australia 2019-2020 Annual Report.

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2020

Matters subsequent to the end of Financial Year

On 21 May 2020, Professor Sanchia Aranda announced her intention to retire as Chief Executive Officer and this occurred on 30 September 2020. An executive search for a new CEO is currently under way; in the meantime Ms Megan Varlow was appointed acting Chief Executive Officer from 1 October 2020.

The Directors are not aware of any other events that have occurred since the end of the reporting period which would significantly impact on the operations or the financial position of the Company disclosed in the Statement of Financial Position as at 30 June 2020 or on the results and cash flows of the Company for that year.

Indemnity and insurance of officers

The Company has indemnified the Directors and Executives of the Company for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium of \$7,164 in respect of a contract to insure the Directors and Executives of the Company against a liability to the extent permitted by the Corporations Act.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Environmental Regulation

The Company is not subject to any significant environment regulations.

Dividends

The Company does not permit any dividends and therefore no dividends have been paid or declared.

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report (cont'd)

30 June 2020

Directors

The names of the Directors of the Company in office during or since the end of the year are:

| Directors Name, Qualifications and Experience | Role | Date Joined | Date Ceased | Board | Executive Committee | Governance Committee | Finance, Risk & Audit Committee |
|--|--|-------------|-------------|-------|---------------------|----------------------|---------------------------------|
| All Directors of the Company in office during the financial year. | | | | | | | |
| 1 July 2019 to 30 June 2020 | | | | | | | |
| Attended / Eligible to attend | | | | | | | |
| Dr Judith Dwyer AM Ph.D MBA BA FAICD FCHSM Dr Dwyer is an adjunct professor in health care management at the Flinders University College of Medicine and Public Health, and a former CEO of Southern Health Care Network in Melbourne and Flinders Medical Centre in Adelaide, having worked in the Australian health system for more than 20 years. She was recently awarded the Sidney Sax Medal for her life-long contribution to the health system. She continues to conduct research focused on health system governance and design with a focus on Aboriginal health policy and services. She is the lead author of the popular textbook Project Management in Health and Community Services. | Director - Board Member - Executive Committee Chair - Governance Committee (until 27 August 2019) | 17 Oct 2013 | 27 Aug 2019 | 2/2 | | 1/1 | |
| Professor George Yeoh BSc(Hons) PhD Professor Yeoh served on the Research Grants Committee of Cancer Council WA from 1999 to 2009, the last eight years of which he was Chair. In 2009, he joined the Board of Cancer Council WA and was appointed President in 2014 and currently a Board member of Cancer Council Australia. He is a Senior Honorary Research Fellow in the School of Molecular Sciences and an Eminentus Professor in the School of Biomedical Sciences at the University of Western Australia. Professor Yeoh undertakes research at the UWA and the Harry Perkins Institute of Medical Research. He has had a long-term interest in liver development and cancer. He was a Board member of The Institute for Respiratory Medicine, Director of the UWA Centre for Cell Therapy and Regenerative Medicine, and a member of the National Health and Medical Research Council's Translational Research Faculty. He served on the Cancer Australia Advisory Council from 2015-2018. | Director - Board (until 20 November 2019) | 11 Dec 2013 | 20 Nov 2019 | 4/4 | | | |
| Dr Anita Green MBBS MSPMed FRACGP FASMF FAICD Dr Green is a Deputy Chair of Cancer Council Queensland and Chair of the Brisbane North Primary Health Network. She works at the University of Queensland Health Service as a General Practitioner, is a Visiting Medical Officer at The Prince Charles Hospital, and was Chief Medical Officer for the 2018 Gold Coast Commonwealth Games. Dr Green is an experienced medical educator, with an appointment as a part-time Senior Lecturer with the University of Queensland School of Human Movement and Nutrition Sciences. She has over 20 years' experience on not-for-profit Boards in the health sector. | Director - Board Member - Finance Risk & Audit Committee (until 20 November 2019) | 3 Feb 2014 | 20 Nov 2019 | 4/4 | | | 5/5 |
| Ms Annette Burke BA Hons Dip Ed MEd MBA ARLP Fellow Ms Burke is Chair of the Board of Cancer Council NT and Fellow of the Australian Rural Leadership Foundation. Having worked for the Abu Dhabi Government as Curriculum Manager at the Centre of Excellence and Director of Executive Education at the Abu Dhabi Chamber of Commerce, Ms Burke negotiated the first ever partnership with five of the world's leading education institutions - Oxford, Cambridge, Harvard, London Business School, Singapore Civil Service College and the National School of Government UK. Ms Burke was Mayor of Palmerston City Council from 1997 to 2007. She has post-graduate qualifications in education, international relationships and negotiations, and business administration. | Director - Board Member - Finance Risk and Audit Committee | 7 Nov 2014 | - | 7/7 | | | 6/7 |
| Professor Jeremy Millar BMedSci MB ChB FRANZCR FACHPMed Professor Millar is also the Board Chair, Cancer Council Victoria; Professor at the Central Clinical School, Monash University; and Council Member, Faculty of Radiation Oncology, Royal Australian and New Zealand College of Radiology (RANZCR). He is the Research Director, Radiation Oncology, Alfred Health, where he has a clinical practice specialising in genito-urinary cancers. Jeremy has more than a 100 publications in peer-reviewed research journals; mostly in brachytherapy, clinical quality registries, or prostate cancer, and has lead academic roles in multiple state, national and international cancer outcomes quality registries at the School of Public Health and Preventive Medicine, Monash University. | Director - Board Deputy Chair - Board (from 27Aug19) Member - Executive Committee (from 27Aug19) | 22 May 2015 | - | 5/7 | 2/2 | | |
| Professor Hugh Harley M.Phil LLB (Hons) BEc (Hons) SF (Fin) Prof Harley has had a diverse career, across the public and private sectors, banking, professional services, and academia. Among executive experience, he was until recently partner in professional services at PwC Australia, specialising in strategy, risk, and governance, and prior to that held senior roles in Commonwealth Bank, including head of Retail Banking and of Group Strategy. Among non-executive roles, he has been Chairman of the Audit Committee of ING Bank Australia and Director of ASB Bank NZ. Prof Harley is Professor of Practice (Global Economy) at the Sydney University Economics School, where he teaches on the current implications of economic history. He is also Strategic Advisor for Seven Consulting Pty Ltd. Prof Harley has previously held Chairman, Treasurer and Board positions in a variety of not-for-profit organisations, across professional services, education, child welfare, and charitable sectors. He was appointed Chairman of Cancer Council Australia on 27 August 2019. | Deputy Chair - Board (until 27Aug19) Chair - Board (from 27 Aug 19) Chair - Executive Committee (from 27Aug19) Ex-officio Member - Governance Committee Ex-officio Member - Finance Risk and Audit Committee | 24 May 2016 | - | 7/7 | 2/2 | 4/4 | 6/7 |
| Ms Sue Hart BA MBUS FAICD Sue Hart has extensive experience in the public and private sectors in both Australia and overseas, and is currently a Director and senior consultant at CMS - an Association Management Company. In this role, Ms Hart provides specialist services to a number of public and private sector boards, assisting with corporate governance, compliance and effectively recording their deliberations, as well as assisting their Chairs in their management roles. She has been awarded a Fellowship of the Australian Institute of Company Directors (AICD) in recognition of her extensive work in corporate governance at a business and personal level, including publication of a number of papers regarding governance processes and provisions in the not for profit sector. | Director - Board Member - Governance Committee (until 19 November 2019) | 16 Aug 2016 | 19 Nov 2019 | 2/3 | | 2/2 | |

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2020

| Directors Name, Qualifications and Experience | Role | Date Joined | Date Ceased | Board | Executive Committee | Governance Committee | Finance, Risk & Audit Committee |
|--|--|-------------|-------------|-------|---------------------|----------------------|---------------------------------|
| | | | | | | | |
| All Directors of the Company in office during the financial year. | | | | | | | |
| 1 July 2019 to 30 June 2020 | | | | | | | |
| <p>Ms Trisha Cashmere BAppSc(Phty)Hons LLB GAICD</p> <p>Ms Cashmere is the consumer representative on Cancer Council Australia's Board. She has practised as a physiotherapist in the public and private sectors, and as a commercial lawyer, and now heads up a growing health business. She has held a number of Board Director positions in the health sector. Ms Cashmere brings personal experience of cancer to her role, as the mother of a child who has twice been diagnosed with cancer.</p> | <p>Director - Board Chair - Finance Risk and Audit Committee (from 27Aug19)</p> <p>Member - Executive Committee (from 27Aug19)</p> | 21 Feb 2017 | - | 7/7 | 2/2 | | 7/7 |
| <p>Mr David Bowker BSc MComm GAICD</p> <p>David is the Vice President of Cancer Council Tasmania and has an Engineering degree from the UK and a Master of Commerce degree from Cape Town University. David has worked for Caltex and de Beers in several countries prior to joining Hydro Tasmania in 1991. During his time at Hydro Tasmania David was the inaugural winner of the Sir Allan Knight Scholarship which allowed him to study energy markets in the UK. David has had roles within Hydro Tasmania in information technology, corporate strategy and energy policy areas. David retired from Hydro Tasmania in December 2017 but still chairs an international working group studying the application of block chain technology to electricity markets. David was the deputy chairman of the board of the National Generators Forum for 6 years, an industry association of electricity generators across Australia. His particular interests lie in strategy and governance and he is Chair of the Governance Committee for Cancer Council Australia and Chair of the Governance Committee for Cancer Council Tasmania.</p> | <p>Director - Board Chair - Governance Committee (from 27Aug19)</p> <p>Member - Executive Committee (from 27Aug19)</p> | 10 Oct 2017 | - | 6/7 | 2/2 | 4/4 | |
| <p>Associate Professor Marion Saville AM MBChB Am Bd (Anat Path & Cytopath) FIAC Grade Dip Med (Clin Epi) GAICD</p> <p>Associate Professor Marion Saville is Executive Director of the Victorian Cytology Service, a position she has held since 2000. Marion Saville is a New Zealand medical graduate who trained in Anatomic Pathology at Northwestern University in Chicago. She went on to complete a fellowship in Cytopathology at East Carolina University and a research fellowship at Georgetown University, focussing on HPV. After completing her pathology training she returned to NZ and later to Australia, where she completed a Graduate Diploma in Clinical Epidemiology at the University of Sydney. Marion has held a number of leadership positions, in cytopathology laboratories in Auckland, Sydney and Melbourne. She is a past president of both the New Zealand and the Australian Societies of Cytology and she chaired the ASC Board of Examiners from 2009 until 2013. She is co-Principal Investigator on the Compass trial, Australia's largest clinical trial, examining the performance of HPV based cervical screening compared with cytology based screening. It is the first large scale clinical trial internationally to assess these screening tests in an HPV vaccinated population. Marion has served on numerous cervical screening advisory committees in Australia and New Zealand. Most recently she was a member of the Renewal Steering Committee, a group established by Australian governments to provide oversight to "Renewal" of the National Cervical Screening Programme. She was also Deputy Chair on the Australian Government's Department of Health and Ageing's Working Party to draft "Clinical Management Guidelines for the Prevention of Cervical Cancer". She is currently chairing the New Zealand Government's, Technical Reference Group who provide expert advice and skills to the National Screening Unit in its implementation of HPV primary screening in the New Zealand National Cervical Screening Programme and is HPV Testing Implementation Consultant for the Ontario Cervical Screening Program for Cancer Care Ontario Canada.</p> | <p>Director - Board</p> | 22 Nov 2017 | - | 7/7 | | | |
| <p>Dr John Laker AO BEc (Hons 1) MSc (Econ) PhD HonDSc</p> <p>Dr Laker was appointed Chairman of ING Bank Australia in February 2020 and was Chairman of the Australian Prudential Regulation Authority (APRA), the regulator of the Australian financial services industry, from 2003 to 2014. An economist by training, Dr Laker had an extensive career in the Reserve Bank of Australia prior to his appointment to APRA, both in Australia and London, and has also worked in the Commonwealth Treasury and the International Monetary Fund (IMF). Currently, Dr Laker is an External Expert for the IMF and has participated in a number of reviews of major banking systems. He is Chairman of The Banking and Finance Oath Ltd, Deputy Chancellor and member of the Council of the University of Technology Sydney and is a Director of Cancer Council NSW. He also lectures at the University of Sydney. Dr Laker was made an Officer of the Order of Australia in 2008 and has won other professional awards for his services to the regulation of the Australian financial system.</p> | <p>Director - Board Member - Governance Committee (from 27Aug19)</p> | 8 May 2018 | - | 7/7 | | 3/3 | |
| <p>Ms Jenny Parker BCom FCA GAICD</p> <p>Jenny has more than 25 years professional services experience, and has been a Partner with Ernst & Young since 1999. Jenny leads the whole of firm in Australia and New Zealand in EY's market facing activities for Health and Life Sciences. Jenny also has a proven track record in leading outsourced internal audit functions, she has also served as the Queensland Managing Partner and on EY's Area Advisory Council responsible for the firm's overall governance and direction. Jenny has held numerous board positions and is currently serving as Deputy Chancellor and Council Member of Queensland University of Technology, Chair of the Catholic Education Council, Member of the Archdiocese of Brisbane Finance Council, Board Member of Mater Hospitals Group Queensland and Board Member of the Queensland Museum and Finance Audit and Risk Management Committee Chair. Jenny is a Fellow of the Institute of Chartered Accountants and member of the Institute of Internal Auditors.</p> | <p>Director - Board Member - Finance Risk and Audit Committee (from 27Aug19)</p> | 18 Dec 2018 | - | 6/7 | | | 3/5 |
| <p>Professor Fran Boyle AM MBBS FRACP PhD GAICD</p> <p>Fran Boyle is a Medical Oncologist at North Sydney's Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She has been involved in clinical trials, supportive care and psychosocial research in breast cancer for the past 20 years. Fran is president elect of the Clinical Oncology Society of Australia, and is a Director of the Breast Cancer Network of Australia.</p> | <p>Director - Board</p> | 07 Feb 2019 | - | 6/7 | | | |

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2020

| Directors Name, Qualifications and Experience | Role | Date Joined | Date Ceased | Board | Executive Committee | Governance Committee | Finance, Risk & Audit Committee |
|---|---|-------------|-------------|-------|---------------------|----------------------|---------------------------------|
| All Directors of the Company in office during the financial year. | | | | | | | |
| 1 July 2019 to 30 June 2020 | | | | | | | |
| Attended / Eligible to attend | | | | | | | |
| <p>Rear Admiral the Honourable Kevin Scarce AC CSC RANR Rtd</p> <p>Kevin Scarce was born in Adelaide, educated at Elizabeth East Primary School and Elizabeth High School, before joining the Royal Australian Navy in 1968. One of Kevin's first postings at sea was on HMAS Sydney in Vietnam. In between his many and increasingly senior postings, Kevin completed a Bachelor of Financial Administration Degree (1998), a Master of Management Economics Degree at the University of NSW, ADFA campus (1990) and a Master's Degree in National Security Strategy at the War College, US National Defence University in Washington DC (1994). In his last appointment in the Australian Defence Force, Kevin temporarily led the Defence Materiel Organisation, which is responsible for acquiring and supporting the entire Australian Defence Force's military equipment throughout Australia and overseas. Following retirement, Kevin formed and led the South Australian Government team charged with expanding the State's defence business opportunities. One of the team's first initiatives, to build air warfare destroyers in Adelaide, was successfully achieved in May 2005 when the Federal Government awarded the contract to a locally-based company. Kevin is President of Novita Children's Services and the Chair of the Adelaide Oval Stadium Management Authority. Kevin is also a Deputy Chairman of Sealey International Pty Ltd, and is a director of a number of other for profit and not-for-profit organisations. Kevin was sworn in as the 34th Governor of South Australia on 8 August 2007, serving more than seven years in the Vice-Regal role. Kevin was awarded the Conspicuous Service Cross in 1994 and appointed an Officer in the Military Division of the Order of Australia in 2004 and a Companion in the General Division of the Order of Australia in 2008 for his service to Australia's defence industry and to the people of South Australia. In December 2009, Flinders University and the University of New England have both bestowed an Honorary Doctorate in recognition of his distinguished service to the nation and to the public of South Australia.</p> | Director - Board (from 21 Oct 2019) (until 11 February 2020) | 21 Oct 2019 | 11 Feb 2020 | 1/3 | | | |
| <p>Mr Roger Buckley JP MC BBA</p> <p>Roger Buckley currently is employed by the Australian National University as a profession staff member. Currently the president/chair of the CCACT. He is an experienced Manager with a demonstrated history of working in the non-profit sector. Skilled in Business Planning, leadership, Human Resources, Financial Management, Event Management and Strategy development/adoption. Over the past ten years he has initiated successful change management strategies to improve operations and to establish good governance and management practices in several not for profit organisations.</p> | Director - Board (from 20 Nov 2019) | 20 Nov 2019 | - | 4/4 | | | |
| <p>Dr Ruth Shean PhD MEd FAICD FIPA AWA FGIA FCIS</p> <p>Ruth worked with the WA Government for 18 years as Director General of the Department of Training and Workforce Development, the Disability Services Commission and the Department for Community Development. She was Commissioner for Public Sector Standards, the government watchdog which oversaw standards within the public sector and assisted with the appointment of government CEOs. Prior to joining government, she was CEO of the Cerebral Palsy Association of WA and Executive Officer of the Australian Council on Smoking and Health. Ruth has held leadership positions on reviews and committees for both state and federal government. She has experience in university governance, having been on governing councils of both Curtin and Murdoch Universities, where she was Pro Chancellor. Ruth has a Master's Degree and a Doctorate of Philosophy from the University of Western Australia. She is a Fellow of the Governance Institute of Australia and the Australian Institute of Company Directors, and is Chair of the National Centre for Vocational Education Research. In November 2019, Ruth was elected as Chairperson of the Cancer Council WA Board and CCWA's President.</p> | Director - Board (from 11 Feb 2020) Member - Governance Committee (from 12 May 2020) | 11 Feb 2020 | - | 3/3 | | 1/1 | |
| <p>Ms Patricia Schmidt LIB GradDipLP Acc.Spec.(Pers.Inj) GAICD</p> <p>Mrs Schmidt is a Board Director of CCQld, appointed in 2019. She is also a member of the Finance, Audit and Risk Management Committee. Tricia is the Senior Partner of Murphy Schmidt Solicitors and has over 35 years' experience as a highly successful litigator and negotiator. Tricia served for 11 years on the Queensland Law Society Specialist Accreditation Board, with 6 years as Chair. She currently holds the positions of Chair of the Queensland Law Society Professional Conduct Committee and of the QLS Committee of Management. She is Chair of the Legal Practice Committee which involves hearing disciplinary applications against legal practitioners. Tricia has been a member of numerous Boards including the Paraplegic and Quadriplegic Association of Queensland, the Catholic Education Council, the Appeal Costs Board and the Board of St Joseph's College, Gregory Terrace. She is a Non-Executive Director of Lexon Insurance Pte Ltd and sits on Lexon's Claims Committee and Underwriting and Risk Committee. Tricia is also a guest lecturer at QUT. She holds a Bachelor of Laws, a Graduate Diploma in Legal Practice, is a Queensland Law Society Accredited Specialist (personal injuries law) and is a Graduate of the Australian Institute of Company Directors.</p> | Director - Board (from 12 May 2020) | 12 May 2020 | - | 1/1 | | | |
| <p>Ms Jennifer Richter AM GAICD FACHSM FACN MBA GradDipHAdmin BA(Comms)</p> <p>Jenny is a Board Director of CCSA being appointed on 16 October 2019 and is a member of the Audit and Risk Committee and a member of the Investment Committee. Jenny currently works as an independent consultant and is a Non-Executive Director on a number of Boards. Jenny's previous executive roles include Deputy Chief Executive for SA Health, a position she held for five years and more recently as CEO of Central Adelaide Local Health Network. Jenny's experience in the health sector commenced as a Registered Nurse. Throughout her career she gained significant leadership experience as an administrator and executive in the public and private hospital sectors, within community nursing, in the private financing sector through public private partnership projects and within the SA public health system. Before joining SA Health, Jenny was an Executive Director with the Plenary Group advising on health service planning and infrastructure projects. This included working with Plenary Group on the Victorian Comprehensive Cancer Centre. Jenny also has significant experience in areas of hospital and health service and facility planning and health service performance, both in Australia and the UK. Jenny is a graduate of the Australian Institute of Company Directors, a Fellow of the Australasian College of Health Service Management and a Fellow of the Royal College of Nursing Australia. She has a Master of Business Administration, a Grad Dip in Health Administration and a Bachelor of Arts. Jenny currently holds directorships with the South Australian Health & Medical Research Institute and the Southern Adelaide Local Health Network where she also chairs the Clinical Governance Board Sub-Committee.</p> | Director - Board (from 12 May 2020) | 12 May 2020 | - | 1/1 | | | |
| <p>Mr Mark Phillips BCom (Hons) MCom FAICD</p> <p>Mr Phillips has more than 30 years' experience in business. In a 20-year career with the Commonwealth Bank of Australia, he was instrumental in the development of a range of new business divisions. Subsequently, Mr Phillips spent more than 10 years as the Chief Executive Officer of various companies listed on the Australian Securities Exchange and as an adviser to businesses and not-for-profit organisations. He is currently Chief Executive Officer of CatholicCare Sydney and is Board Chair of Cancer Council NSW and also a Board Director of Access Programs Australia and Board Co-Chair of End Street Sleeping</p> | Director - Board (from 22 Jun 2020) | 22 Jun 2020 | - | 0/0 | | | |

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2020

Chief Executive Officer

Professor Sanchia Aranda was appointed as the CEO to the Company on 3 August 2015.

Company Secretary

Lisa Miskell was appointed Company Secretary on 11 March 2019.

Contributions on winding up


In the event of the Company being wound up, ordinary members are required to contribute a maximum of \$10 each.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on the following page.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2) (a) of the Corporations Act 2001.

On behalf of the Directors



Professor Hugh Harley
Chair



Ms Trisha Cashmere

Sydney
13 October 2020

DECLARATION OF INDEPENDENCE BY LEAH RUSSELL TO THE DIRECTORS OF CANCER COUNCIL AUSTRALIA

As lead auditor of Cancer Council Australia for the year ended 30 June 2020, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the section 60-40 of the *Australian Charities and Not-for-profit Commission Act 2012* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.



Leah Russell
Partner

BDO East Coast Partnership

Sydney, 13 October 2020

Cancer Council Australia (ABN 91 130 793 725)
Statement of profit or loss and other comprehensive income
As at 30 June 2020

| | Notes | 2020 | 2019 |
|--|-----------------|-------------------|-------------------|
| | | \$ | \$ |
| Revenue | | | |
| Member subscriptions | 1(c)(i), 4 | 6,595,933 | 7,517,930 |
| Grants income | 1(c)(ii), 4 | 5,143,481 | 5,089,322 |
| Royalties | 1(c)(iv), 4 | 3,218,551 | 3,403,579 |
| Bequests | 1(c)(v), 4 | 2,474,999 | 2,727,931 |
| Donations | 1(c)(v), 4 | 2,110,470 | 1,969,513 |
| Central marketing fund income | 1(c)(vi), 4, 22 | 1,349,888 | 218,926 |
| Interest income | 1(c)(vii), 4 | 104,311 | 144,335 |
| Other revenue | 1(c)(viii), 4 | 656,020 | 293,977 |
| Total revenue | | 21,653,653 | 21,365,513 |
| Expenses | | | |
| Prevention & policy | | 6,310,618 | 6,579,895 |
| Sale of sun protection products | 22 | 1,843,500 | 726,143 |
| Information & support | | 1,597,659 | 1,876,279 |
| Media & communication | | 874,371 | 881,617 |
| Marketing of programs & services | 22 | 569,480 | 713,984 |
| Research | 22 | 442,975 | 504,138 |
| Distribution to members for local programs | 22 | 8,930,583 | 8,516,182 |
| Total mission related expense | | 20,569,186 | 19,798,238 |
| Fundraising expense | | 679,274 | 975,759 |
| Administration & governance | 22 | 273,391 | 334,689 |
| Total expense | | 21,521,851 | 21,108,686 |
| Income tax expense | 1(g) | - | - |
| Net surplus after income tax expense for the year attributable to the members of Cancer Council Australia | | 131,802 | 256,827 |
| Other comprehensive income for the year net of tax | | - | - |
| Total comprehensive income for the year attributable to the members of Cancer Council Australia | | 131,802 | 256,827 |

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of financial position
As at 30 June 2020

| | Notes | <u>2020</u> | <u>2019</u> |
|--------------------------------------|-------|-------------------|-------------------|
| | | \$ | \$ |
| Assets | | | |
| Current assets | | | |
| Cash & cash equivalents | 6 | 6,457,896 | 11,758,756 |
| Trade & other receivables | 7 | 8,231,272 | 7,014,022 |
| Other current assets | 8 | 3,343,030 | 2,315,287 |
| Total current assets | | 18,032,198 | 21,088,065 |
| Non-current assets | | | |
| Plant & equipment | 9 | 267,633 | 328,161 |
| Intangible assets | 10 | 294,454 | - |
| Right of use assets | 11 | 683,905 | - |
| Total non-current assets | | 1,245,992 | 328,161 |
| Total Assets | | 19,278,190 | 21,416,226 |
| Liabilities | | | |
| Current liabilities | | | |
| Trade & other payables | 12 | 14,153,325 | 17,091,327 |
| Provision for employee benefits | 13 | 366,535 | 334,781 |
| Lease liability | 17 | 408,630 | - |
| Total current liabilities | | 14,928,490 | 17,426,108 |
| Non-current liabilities | | | |
| Provision for employee benefits | 13 | 60,817 | 41,492 |
| Provision for office make good | 13 | 168,278 | 168,278 |
| Lease liability | 17 | 526,261 | - |
| Total Non-Current Liabilities | | 755,356 | 209,770 |
| Total Liabilities | | 15,683,846 | 17,635,878 |
| Net Assets | | 3,594,344 | 3,780,348 |
| Funds | | | |
| General funds | | 2,205,883 | 2,456,868 |
| Research & Special Projects Reserve | | 1,388,461 | 1,323,480 |
| Total Funds | | 3,594,344 | 3,780,348 |

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of changes in equity
For the year ended 30 June 2020

| | General Funds | Research & Special Projects Reserve | Total Funds |
|---|------------------|--|------------------|
| Balance at 1 July 2018 | 2,456,868 | 1,066,653 | 3,523,521 |
| Surplus after income tax for the year | 256,827 | - | 256,827 |
| Other comprehensive income for the year | - | - | - |
| Transfer to/(from) reserves | (256,827) | 256,827 | - |
| Transfer (to)/from liabilities | - | - | - |
| Balance at 30 June 2019 | 2,456,868 | 1,323,480 | 3,780,348 |
| Balance at 1 July 2019 | 2,456,868 | 1,323,480 | 3,780,348 |
| Adjust for change in accounting policy | (317,806) | - | (317,806) |
| Surplus after income tax for the year | 131,802 | - | 131,802 |
| Other comprehensive income for the year | - | - | - |
| Transfer to reserves | (64,981) | 64,981 | - |
| Balance at 30 June 2020 | 2,205,883 | 1,388,461 | 3,594,344 |

Nature and Purpose of Reserves

Research & Special Projects Reserve

This reserve relates to funds received by the Company for use in research and special projects.

Cancer Council Australia (ABN 91 130 793 725)
Statement of cash flows
For the year ended 30 June 2020

| | Notes | <u>2020</u> \$ | <u>2019</u> \$ |
|---|----------|--------------------------------|---------------------------------|
| <u>Cash flows from operating activities:</u> | | | |
| Receipts from member subscriptions, donations and other income (inclusive of GST) | | 10,086,109 | 18,002,723 |
| Payments to suppliers, employees and member bodies (inclusive of GST) | | (13,748,488) | (11,240,995) |
| Interest received | | 104,311 | 144,335 |
| Net cash (used in)/ provided by operating activities | 18 | <u>(3,558,068)</u> | <u>6,906,063</u> |
| <u>Cash flows from investing activities:</u> | | | |
| Payments for term deposits | | (1,036,256) | (64,080) |
| Payment for intangible asset | 10 | (294,454) | - |
| Proceeds from sale of plant and equipment | | 321 | |
| Payment for purchase of plant and equipment | 9 | <u>(41,624)</u> | <u>(87,216)</u> |
| Net cash used in investing activities | | <u>(1,372,013)</u> | <u>(151,296)</u> |
| <u>Cash flows from financing activities:</u> | | | |
| Repayment of lease liability - principal | | <u>(370,779)</u> | - |
| Net cash used in financing activities | | <u>(370,779)</u> | - |
| Net increase/(decrease) in cash & cash equivalents | | (5,300,860) | 6,754,767 |
| Cash & cash equivalents at the beginning of the year | | <u>11,758,756</u> | <u>5,003,989</u> |
| Cash & cash equivalents at the end of the year | 6 | <u><u>6,457,896</u></u> | <u><u>11,758,756</u></u> |

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020

Note 1. Statement of significant accounting policies

Cancer Council Australia ("the Company") has adopted Australian Accounting Standards Reduced Disclosure Requirements as set out in AASB 1053. The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements of the Australian Accounting Standards Board ("AASB") and the ACNC Act 2012.

The Company is a not-for-profit entity and incorporated Company limited by guarantee domiciled in Australia.

The financial report was authorised for issue by the Directors on 13 October 2020.

NEW, REVISED OR AMENDED ACCOUNTING STANDARDS AND INTERPRETATIONS ADOPTED

Cancer Council Australia has adopted all of the new, revised or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period.

Any new, revised or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant net impact on the financial performance or position of the Company. There are no other new interpretations expected to have any significant impact on the Company's financial report that are issued and not yet applicable.

The following Accounting Standards and Interpretations have been adopted by Cancer Council Australia for the reporting period ended 30 June 2020:

AASB 16 Leases

This standard has been adopted from 1 July 2019. The standard replaces AASB 117 'Lease' and for lessees eliminates the classifications of operating leases and finance leases. Except for short-term leases and leases of low-value assets, right-of-use assets and corresponding lease liabilities are recognised in the statement of financial position.

AASB 16 was adopted using the modified retrospective approach and as such the comparatives have not been restated. The company elected to measure right-of-use asset at the date of initial application as if it had always been in place. Therefore, there was an opening adjustment to accumulated surplus at the date of initial application at 1 July 2019 of \$317,806.

Impact of adoption

In applying AASB 16 for the first time, the Company has used the following practical expedients permitted by the standard:

- Accounting for leases with a remaining lease term of 12 months as at 1 July 2019 as short-term leases;
- Excluding any initial direct costs from the measurement of right-of-use assets;
- Not applying AASB 16 to contracts that were not previously identified as containing a lease.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

AASB 15 Revenue from Contracts with Customers

The company has adopted AASB 15 from 1 July 2019. AASB 15 establishes a comprehensive five-step framework for recognising revenue. AASB 15 applies to all revenue arising from contracts with customers, unless those contracts are in the scope of other standards. The core principle of the standard is that an entity shall recognise revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The standard requires entities to exercise judgment, taking into consideration all the relevant facts and circumstances when applying each step of the model to contracts with their customers.

The standard introduced a new contract-based revenue recognition model with a measurement approach that is based on an allocation of the transaction price. This is described further in the accounting policies below.

Contracts with customers are presented in an entity's statement of financial position as a contract liability, a contract asset, or a receivable, depending on the relationship between the entity's performance and the customer's payment. Customer acquisition costs and costs to fulfil a contract can, subject to certain criteria, be capitalised as an asset and amortised over the contract period.

AASB 1058 Income of Not-for-Profit Entities

The company has adopted AASB 1058 from 1 July 2019. The standard replaces AASB 1004 "Contributions" in respect to income recognition requirements for not-for-profit entities. The timing of income recognition under AASB 1058 is dependent upon whether the transaction gives rise to a liability or other performance obligation at the time of receipt.

Income under the standard is recognised where: an asset is received in a transaction, such as by way of grant, bequest or donation; there has either been no consideration transferred, or the consideration paid is significantly less than the asset's fair value; and where the intention is to principally enable the entity to further its objectives.

For transfers of financial assets to the entity which enable it to acquire or construct a recognisable non-financial asset, the entity must recognise a liability amounting to the excess of the fair value of the transfer received over any related amounts recognised. Related amounts recognised may relate to contributions by owners, AASB 15 revenue or contract liability recognised, lease liabilities in accordance with AASB 16, financial instruments in accordance with AASB 9, or provisions in accordance with AASB 137. The liability is brought to account as income over the period in which the entity satisfies its performance obligation.

If the transaction does not enable the entity to acquire or construct a recognisable non-financial asset to be controlled by the entity, then any excess of the initial carrying amount of the recognised asset over the related amounts is recognised as income immediately. Where the fair value of volunteer services received can be measured, a private sector non-for-profit entity can elect to recognise the value of those services as an asset where asset recognition criteria are met or otherwise recognise the value as an expense.

Impact of AASB 15 & 1058 adoption

The adoption of AASB 15 & 1058 impacted the financial statements through the disclosure of revenue for receipts that are received and passed on directly to members for delivery of local programs. These receipts had previously been treated as agency revenue and not recognised in the financial statements. There were no adjustments required to retained earnings.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

BASIS OF PREPARATION

These general purpose financial statements have been prepared in accordance with the Australian Charities and Not-for-profit Commission Act 2012 and Australian Accounting Standards - Reduced Disclosure Requirements and Interpretations issued by the AASB. The company is a not-for-profit for financial reporting purposes under Australian Accounting Standards.

REPORTING BASIS AND CONVENTIONS

The financial report has been prepared on an accruals basis (except for the cash flow information and as noted in 1 (d)(i)) and is based on historical costs and does not take into account changing money values or, except where specifically stated, current valuations of non-current assets. The following material accounting policies, which are consistent with the previous period have been adopted in the preparation of this report.

All amounts are in Australian dollars.

ACCOUNTING POLICIES

(a) Plant & equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

| <u>Class of plant and equipment</u> | <u>Useful life</u> |
|-------------------------------------|--------------------|
| Office equipment | 3 - 5 years |
| Computer equipment | 4 years |
| Leasehold improvements | 10 years |

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss.

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(b) Provision for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

(c) Revenue Recognition - Accounting policy applicable from 1 July 2019

(i) Member organisation subscriptions and revenue forwarded to members

Member subscription revenue is recognised on a basis that reflects the timing, nature and value of the benefits provided. Income received from bequests, donations and royalties collected by the Company is distributed to members to deliver local cancer programs and services.

| | <u>2020</u> | <u>2019</u> |
|---|------------------|------------------|
| | \$ | \$ |
| The details of members' subscriptions received during the year follow: | | |
| Member subscriptions funding national projects | 6,595,933 | 7,517,930 |
| Amounts forwarded to the Company's state and territory members for delivery of local programs and services: | <u>8,970,230</u> | <u>7,886,577</u> |

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(ii) Grants

Revenue from government grants received under enforceable agreements, where there are sufficiently specific performance obligations imposed, is deferred until the obligations are satisfied. If the performance obligations are not sufficiently specific, revenue will be recognised upon receipt.

Capital grants are recognised as income when (or as) the Company satisfies its obligations under the transfer. Capital grants are types of grants where the Company receives a financial asset to acquire or construct a non-financial asset to identified specifications; retains control of the non-financial asset (i.e. for its own use); and the transaction is enforceable.

(iii) Revenue from contracts with customers

The terms and conditions of each contract are reviewed to determine if the requirements of AASB 15 "Revenue from Contracts with Customers" are met. If AASB 15 applies to a transaction or part of a transaction, Cancer Council Australia applies the general principles of this standard to determine the appropriate revenue recognition. Under AASB 15, revenue is recognised when (or as) the performance obligation is satisfied. Any income received where the performance obligation is not yet satisfied at the reporting date, is recorded as deferred income.

(iv) Royalties

Royalties are earned from the licensing of the use of the Company's endorsement on consumer products and are recorded on an accruals basis as advised by the licensee.

(v) Bequests and Donations

Cancer Council Australia, in common with most organisations dependent upon contributions, is unable to establish absolute control over all voluntary donations, due to their nature, prior to their initial entry into the accounting records. Therefore, revenue from fundraising, including donations and bequests, is recognised when received or receivable.

(vi) Central Marketing Fund (CMF)

The Central Marketing Fund income received by the Company is contributed by product licensees for the implementation of campaigns to drive incremental sales of Cancer Council branded products and for key brand-building activities that also help to build sun safety awareness in the community. Such contributions received are subject to reciprocal transfer and are recorded as a liability upon receipt. Income is recorded when conditions/payments associated with the contributions are met.

(vii) Interest

Interest income is recognised as interest accrues using the effective interest method. The effective interest method uses the effective interest rate which is the rate that exactly discounts the estimated future cash receipts over the expected life of the financial asset.

(viii) Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

All revenue is stated net of the amount of goods and services tax (GST).

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(d) Right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

A right-of-use asset is depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Company expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

(e) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in the normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when: it is expected to be settled in the normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within twelve months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. All other liabilities are classified as non-current.

(f) Lease Liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the entity's incremental borrowing rate. Lease payments comprise fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expenses in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties.

When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(g) Taxation

The Company is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended; it is therefore exempt from income tax. This exemption has been confirmed by the Australian Taxation Office. The Company holds deductible gift recipient (DGR) status.

(h) Cash & cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.

(i) Trade & other receivables

Other receivables are recognised at amortised cost, less any provision for impairment.

(j) Financial instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the entity commits itself to either the purchase or sale of the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transaction costs, except where the instrument is classified "at fair value through profit or loss", in which case transaction costs are expensed to profit or loss immediately.

Classification and subsequent measurement

Financial instruments are subsequently measured at fair value, amortised cost using the effective interest method, or cost.

Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment, and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method.

The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) over the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(k) Goods and Services Tax (GST)

Revenue, expenses and plant & equipment are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in balance sheet are shown inclusive of GST. Cash flows are presented in the cash flow statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

(l) Trade & other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(m) Comparative figures

Comparative figures of the Company for the previous 12 month period are included throughout these statements.

(n) Use of the term "surplus"

The Company is a not-for-profit organisation. As such, the term "profit" is not applicable and the term "surplus" is used where required.

(o) Critical accounting estimates and judgements

The Directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Estimation of useful lives of assets

The Company determines the estimated useful lives and related depreciation and amortisation charges for its plant and equipment. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete. Leasehold improvements are depreciated over the term of the lease of the property.

Long service leave provision

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

Determining whether a grant contains enforceable and sufficiently specific obligations

The interaction between AASB 15 and AASB 1058 requires management to assess whether the government grants and other funding received need to be accounted for under AASB 15 or AASB 1058. Key to this assessment is whether the government grants and other funding agreements contain:

- a contract with a customer that creates 'enforceable' rights and obligations, and
- the contract includes 'sufficiently specific' performance obligations.

Critical judgement was applied by management in assessing whether a promise is 'sufficiently specific', taking into account all facts and circumstances and any conditions specified in the arrangement (whether explicit or implicit) regarding the promised goods or services, including conditions regarding:

- the nature or type of the goods or services
- the cost or value of the goods or services
- the quantity of the goods or services, and
- the period over which the goods or services must be transferred.

(p) Provisions

Provisions are recognised when the Company has a present (legal or constructive) obligation as a result of a past event, it is probable the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. The make good provision represents the estimated costs to make good the premises leased by the Company at the end of the respective lease terms.

Note 2. Nature of the Company

The Company is an incorporated Company Limited by Guarantee under the *Corporations Act 2001*.

There were 8 members of the Company at 30 June 2020.

The members (being the state and territory Cancer Councils) undertake to contribute an amount not exceeding \$10 to the assets of the Company in the event of it being wound up.

Note 3. Economic dependence

The ability of the Company to maintain its operations is dependent, among other things, on the continuing support of the various state and territory members by way of member subscriptions.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 4. Revenue

| | <u>2020</u> | <u>2019</u> |
|--|-------------------|-------------------|
| | \$ | \$ |
| <u>Revenue includes:</u> | | |
| Membership subscriptions (also refer to note 1(c)(i)) | 6,595,933 | 7,517,930 |
| Grant income | 5,143,481 | 5,089,322 |
| Central Marketing Fund income (also refer to notes 1(c)(vi), 22) | 1,349,888 | 218,926 |
| JobKeeper payments | 307,500 | - |
| Research & special projects | 181,266 | 174,363 |
| Interest income | 104,311 | 144,335 |
| Cashflow boost | 50,000 | - |
| Other revenue | 117,254 | 119,614 |
| Revenue directed to national programs | <u>13,849,633</u> | <u>13,264,490</u> |
| | | |
| Royalties for licensed sun protection products | 3,218,551 | 3,403,579 |
| Bequests | 2,474,999 | 2,727,931 |
| Donations | 2,110,470 | 1,969,513 |
| Revenue directed to Members for local programs | <u>7,804,020</u> | <u>8,101,023</u> |
| | | |
| Total revenue | <u>21,653,653</u> | <u>21,365,513</u> |

Note 5. Other expenses not disclosed elsewhere

| | | |
|---------------------------|------------------|------------------|
| Employee benefits expense | <u>4,065,759</u> | <u>4,258,102</u> |
|---------------------------|------------------|------------------|

Note 6. Cash & cash equivalents

| | | |
|--------------|------------------|-------------------|
| Cash on hand | 750 | 461 |
| Cash at bank | <u>6,457,146</u> | <u>11,758,295</u> |
| | <u>6,457,896</u> | <u>11,758,756</u> |

Note 7. Trade & other receivables

| | | |
|--|------------------|------------------|
| <u>Current</u> | | |
| Royalties receivable | 299,186 | 383,675 |
| Other amounts receivable | 2,664,376 | 559,481 |
| Subscriptions due from member cancer organisations | <u>5,267,710</u> | <u>6,070,866</u> |
| | <u>8,231,272</u> | <u>7,014,022</u> |

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 8. Other current assets

| | | |
|---|-------------------------|-------------------------|
| Financial assets at amortised cost - term deposit | 3,311,256 | 2,275,000 |
| Prepayments | <u>31,774</u> | <u>40,287</u> |
| | <u><u>3,343,030</u></u> | <u><u>2,315,287</u></u> |

Note 9. Plant & equipment

| | | |
|------------------------------------|-----------------------|-----------------------|
| Office equipment | | |
| - Office equipment, at cost | 384,435 | 377,737 |
| - Accumulated depreciation | <u>(369,050)</u> | <u>(371,455)</u> |
| Total office equipment | <u>15,385</u> | <u>6,282</u> |
| | | |
| - Computer equipment, at cost | 288,184 | 261,621 |
| - Accumulated depreciation | <u>(189,760)</u> | <u>(166,059)</u> |
| Total computer equipment | <u>98,424</u> | <u>95,562</u> |
| | | |
| Leasehold improvements | | |
| - Leasehold improvements, at cost | 702,212 | 702,212 |
| - Accumulated depreciation | <u>(548,389)</u> | <u>(475,895)</u> |
| Total leasehold improvements | <u>153,823</u> | <u>226,317</u> |
| | | |
| Total plant & equipment | <u><u>267,633</u></u> | <u><u>328,161</u></u> |

The net surplus has been determined after charging the following specific expense:

| | | |
|-----------------------------------|----------------|---------------|
| Depreciation of plant & equipment | <u>101,910</u> | <u>94,258</u> |
|-----------------------------------|----------------|---------------|

| | Office Equipment | Computer Equipment | Leasehold Improvements | Total |
|------------------------|-----------------------------|-------------------------------|-----------------------------------|-----------------------|
| | \$ | \$ | \$ | \$ |
| Balance at 1 Jul 2018 | 8,404 | 27,988 | 298,811 | 335,203 |
| Additions | 2,137 | 85,079 | | 87,216 |
| Depreciation expense | <u>(4,259)</u> | <u>(17,505)</u> | <u>(72,494)</u> | <u>(94,258)</u> |
| Balance at 30 Jun 2019 | 6,282 | 95,562 | 226,317 | 328,161 |
| Additions | 12,748 | 28,876 | | 41,624 |
| Disposal | | (242) | | (242) |
| Depreciation expense | <u>(3,645)</u> | <u>(25,772)</u> | <u>(72,494)</u> | <u>(101,910)</u> |
| Balance at 30 Jun 2020 | <u><u>15,385</u></u> | <u><u>98,424</u></u> | <u><u>153,823</u></u> | <u><u>267,633</u></u> |

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 10. Intangible Asset

| | <u>2020</u> | <u>2019</u> |
|-------------------------|----------------|-------------|
| | \$ | \$ |
| Software at cost | 294,454 | - |
| Total Intangible assets | <u>294,454</u> | <u>-</u> |

Software is measured on the basis of the cost of acquisition or development of software less subsequent accumulated amortisation and accumulated impairment losses. Software is amortised from the date that it is available for use over its estimated useful life. This software was available for use from July 2020 and will be amortised over a period of eight years.

Note 11. Lease

| | <u>2020</u> | <u>2019</u> |
|---------------------------------|--------------------|-------------|
| | \$ | \$ |
| <u>Right-of-use-asset (ROU)</u> | | |
| Right-of-use-asset | 3,039,581 | - |
| Less: accumulated depreciation | <u>(2,355,676)</u> | <u>-</u> |
| Total right-of-use-asset | <u>683,905</u> | <u>-</u> |

*ROU are Cancer Council Australia's right to use leased asset over the life of their leases and have come into effect from 1 July 2019 due to the application of the new lease standard AASB 16. The asset is amortised over its useful life assessed as 10 years.

Movement table

| | |
|--------------------------|---------|
| Opening on transition | 987,976 |
| Additions | - |
| Depreciation | 304,071 |
| Total right-of-use-asset | 683,905 |

Note 12. Trade & other payables

| <u>Current</u> | | |
|--|-------------------|-------------------|
| Trade creditors | 511,379 | 922,643 |
| Sundry creditors | 1,286,788 | 2,989,228 |
| Contract liability/ Income in advance – grants | 3,047,336 | 5,265,812 |
| Amounts due to members | <u>9,307,822</u> | <u>7,913,644</u> |
| | <u>14,153,325</u> | <u>17,091,327</u> |

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 13. Provisions

| | <u>2020</u> | <u>2019</u> |
|------------------------|----------------|----------------|
| | \$ | \$ |
| <u>Current</u> | | |
| Employee benefits | 366,535 | 334,781 |
| | <u>366,535</u> | <u>334,781</u> |
| <u>Non-Current</u> | | |
| Employee benefits | 60,817 | 41,492 |
| Office make good | 168,278 | 168,278 |
| | <u>229,095</u> | <u>209,770</u> |

Note 14. Commitments

Non-cancellable operating lease commitments

Non-cancellable operating leases contracted but not capitalised in the financial statements:

Payable

| | | |
|---|----------|------------------|
| Not longer than one year | - | 465,979 |
| Longer than one year but not longer than five years | - | 1,094,452 |
| | <u>-</u> | <u>1,560,431</u> |

Priority-Driven Research Grant Commitments

Commitments contracted for, but not recognised as liabilities at the balance date, and expected to be funded from annual subscription fees from member:

Payable

| | | |
|---|----------------|----------------|
| Not longer than one year | 230,983 | 196,000 |
| Longer than one year but not longer than five years | 93,842 | 204,825 |
| | <u>324,825</u> | <u>400,825</u> |

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 15. Key management personnel disclosures

Compensation

The aggregate compensation made to Directors and key management personnel of the Company is set out below:

| | <u>2020</u> | <u>2019</u> |
|---|----------------|----------------|
| | \$ | \$ |
| Compensation paid to key management personnel | <u>900,945</u> | <u>972,580</u> |

Directors' reasonable travel and accommodation expenses are paid for by the Company, but otherwise Directors receive no other payments.

Note 16. Remuneration of the Auditor

During the year, the following fees were paid or payable for services provided by the Auditor, BDO Audit Pty Ltd to the Company:

| | <u>2020</u> | <u>2019</u> |
|--|---------------|---------------|
| | \$ | \$ |
| Auditors of the Group – BDO East Coast Partnership Audit and review of the financial statements | <u>25,000</u> | <u>24,600</u> |

Note 17. Lease Liabilities

| | | |
|-----------------|----------------|----------|
| Lease Liability | | |
| Current | 408,630 | - |
| Non-current | 526,261 | - |
| | <u>934,891</u> | <u>-</u> |

CCA adopted AASB 16 retrospectively from 1 July 2019, but has not restated comparatives for the 2019 reporting period, as permitted under the specific transitional provisions in the standard. As a result, the above lease liabilities represent the present value of the remaining lease payment, discounted using the company's incremental borrowing rate. There has been no new leases or modification since adoption. The lease liability includes judgement and estimates for the interest rate used and the lease terms.

The lease term is until September 2022.

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)

Note 18. Reconciliation of cash flows from operating activities with net surplus for the year

| | <u>2020</u> | <u>2019</u> |
|---|--------------------|------------------|
| | \$ | \$ |
| Net surplus/(deficit) for the year | 131,802 | 256,827 |
| Non-cash flows in net surplus for the year: | | |
| Depreciation | 405,791 | 94,258 |
| Changes in assets and liabilities: | | |
| (Increase)/Decrease in trade and other receivables | (1,217,250) | 400,493 |
| (Increase)/Decrease in other assets | 8,513 | (3,131) |
| Increase in provisions | 51,079 | 28,010 |
| Increase/(Decrease) in trade and other payables | <u>(2,938,003)</u> | <u>6,129,606</u> |
| Net cash(used in)/provided in the operating activities* | <u>(3,558,068)</u> | <u>6,906,063</u> |

* Significant funding received in 2018/19 year was used in 2019/20 to deliver the national Bowel Cancer Screening media campaign.

Note 19. Events subsequent to reporting date

On 21 May 2020, Professor Sanchia Aranda announced her intention to retire as Chief Executive Officer and this occurred on 30 September 2020. An executive search for a new CEO is currently under way; in the meantime Ms Megan Varlow was appointed acting Chief Executive Officer from 1 October 2020.

The Directors are not aware of any other events that have occurred since the end of the reporting period which would significantly impact on the operations or the financial position of the Company disclosed in the Statement of Financial Position as at 30 June 2020 or on the results and cash flows of the Company for that year.

Note 20. Contingent liabilities

There are no contingent liabilities at the end of the year other than those identified elsewhere in the report.

| | | |
|---|----------------|----------------|
| Bank guarantee in respect of operating leases | <u>275,000</u> | <u>275,000</u> |
|---|----------------|----------------|

Note 21. Related party transactions

Key management personnel

Disclosures relating to key management personnel are set out in note 15.

Transactions with related parties

The only related parties were the members and that there were no related party transactions other than those already disclosed during the current and previous financial year.

Receivable from and payable to related parties

Other than those already disclosed, there were no trade receivables from or trade payables to related parties at the current and previous reporting date.

There were no loans to or from related parties at the current and previous reporting date.

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2020 (cont'd)
Loans to/from related parties

Note 22. Expenditure

Sale of sun protection products

Cancer Council Australia (CCA) manages retail and licensing arrangements to distribute sun protection products, and to promote preventative behaviours to reduce the incidence of skin cancers. Income generated from this activity is recognised in CCA's accounts as Royalties, and in CCA's state and territory members' financial accounts as sales of sun protection products.

During the 2019/2020 summer period CCA invested in a media campaign to promote Cancer Council sun protection products and the five forms of sun protection. This campaign was funded by CCA's licensees via income contributed to CCA's Central Marketing Fund and explains the significant increase in both income and expense compared to the 2018/2019 year.

Research

Collectively, Cancer Council Australia and its state and territory members fund approximately \$60 million of cancer research in Australia each year, more than any other non-government entity. Reflecting long-standing practice, CCA's investment in research is restricted to priority research programs and partnership grants. More information can be found in the Cancer Council Research Report found at cancer.org.au.

Administration and governance

Administration and governance costs reflect costs required to operate as a corporate entity and provide best practice governance. Recent trends in these costs reflect the ongoing focus on improved governance and performance.

Other costs incurred to support the delivery of mission and fundraising work, including a proportion of our information technology, human resources, learning and development, financial administration and occupancy costs, are attributed to each functional area of Cancer Council Australia's work to reflect the cost of delivering these functions.

Marketing of programs & services

Cancer Council Australia and its state and territory members work together towards a shared vision of a cancer free future. To achieve this we invest each year in research, prevention, and advocacy programs, and fund many support and information services.

Our Marketing teams work is to increase the awareness of the programs we fund, and of the services we provide to Australians with a cancer diagnosis, and their families and friends.

More information on the impact of Cancer Council's work can be found at cancer.org.au.

Distribution to Members for local programs & services

Cancer Council Australia supports its state and territory members financially with an annual distribution towards local cancer programs and services.

Note 23. Company Details

The registered office and principal place of business of the Company is:

Level 14, 477 Pitt Street
Sydney NSW 2000 Australia

The Company operates entirely in Australia as a Health Promotion Charity.


Cancer Council Australia (ABN 91 130 793 725)

Directors' Declaration

In the Directors' opinion:

1. The attached financial statements and notes comply with the ACNC Act 2012, Australian Accounting Standards – Reduced Disclosure Requirements, the ACNC Regulations 2013 and other mandatory professional reporting requirements;
2. The attached financial statements and notes thereto give a true and fair view of the Company's financial position as at 30 June 2020 and of its performance for the financial year ended on that date; and
3. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the Directors by:



Professor Hugh Harley

Chair



Ms Trisha Cashmere

Sydney
13 October 2020

INDEPENDENT AUDITOR'S REPORT

To the members of Cancer Council Australia

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Cancer Council Australia (the registered entity), which comprises the statement of financial position as at 30 June 2020, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the Directors' declaration.

In our opinion the accompanying financial report of Cancer Council Australia, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) Giving a true and fair view of the registered entity's financial position as at 30 June 2020 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Those charged with governance are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the registered entity's annual report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The Directors of the Company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, Directors are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the registered entity's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO East Coast Partnership

BDO

Leah Russell
Partner

Sydney, 15 October 2020